• Explore /
  • Poster
  • / PREDICTOR (UNICANCER GEP11): Randomized phase II study of preoperative afatinib in untreated head and neck squamous cell carcinoma (HNSCC) patients.

PREDICTOR (UNICANCER GEP11): Randomized phase II study of preoperative afatinib in untreated head and neck squamous cell carcinoma (HNSCC) patients.

Abstract Poster

Authors

null

Christophe Le Tourneau

Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris, Paris, France

Christophe Le Tourneau , Jean-Pierre Delord , Gilles Dolivet , Olivier Malard , Jérôme Fayette , Olivier Capitain , Caroline Even , Caroline Hoffmann , Sebastien Vergez , Lionnel Geoffrois , Frederic Rolland , Philippe Zrounba , Laurent Laccourreye , Joel Guigay , Ivan Bieche , Jerzy Klijanienko , Nicolas Aide , Valerie Benavent , Jocelyn Gal , Stephane Temam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT01415674

Citation

J Clin Oncol 35, 2017 (suppl; abstr 6021)

DOI

10.1200/JCO.2017.35.15_suppl.6021

Abstract #

6021

Poster Bd #

9

Abstract Disclosures

Similar Posters

First Author: Christophe Le Tourneau

First Author: Lei Liu

First Author: Zhigong Wei

First Author: Qinglian Tang